Lantheus Holdings Inc

LNTH

Company Profile

  • Business description

    Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

  • Contact

    201 Burlington Road
    South Building
    BedfordMA01730
    USA

    T: +1 978 671-8001

    E: [email protected]

    https://www.lantheus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    808

Stocks News & Analysis

stocks

Undervalued ASX share with plan to mitigate tariff risk

Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks

Earnings up but shares overvalued for ASX gold miner

Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,300.7021.30-0.23%
CAC 408,239.1813.550.16%
DAX 4024,308.7868.890.28%
Dow JONES (US)47,544.59337.470.71%
FTSE 1009,653.828.200.09%
HKSE26,444.3810.680.04%
NASDAQ23,637.46432.591.86%
Nikkei 22550,219.62292.70-0.58%
NZX 50 Index13,402.6611.070.08%
S&P 5006,875.1683.471.23%
S&P/ASX 2009,017.4011.40-0.13%
SSE Composite Index4,005.448.500.21%

Market Movers